Rare sugars curb appetite and mimic diabetes drugs in mice
Can rare sugars help control appetite and fight obesity? New research in mice suggests sweet solutions may lie in your ...
Tag: GLP-1
US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies
Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening ...
New gene switch may lead to precise treatments for metabolic diseases
ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to ...
What causes behavioral side effects in popular weight loss drugs?
GLP1R gene variants link to cardiometabolic traits and behavioral changes, but findings suggest behavioral effects of GLP1RA are indirect Study: ...
Why do people with obesity, but without diabetes, start taking semaglutide?
Factors such as sex, type of insurance plan, and the use of common medications influenced whether individuals with obesity but ...
Benefits and risks of popular weight-loss drugs revealed
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
How gut microbes and hormones shape your sweet tooth
Researchers discover a gut-microbe-driven pathway involving pantothenate and GLP-1 that could revolutionize sugar consumption management and metabolic health strategies. Study: ...
Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication
Anti-obesity medications linked to reduced alcohol use, possibly due to effects on cravings and reward systems, with behavioral strategies also ...
Squid-inspired technology could replace needles for medications and vaccines
Using jet propulsion inspired by squid, researchers demonstrate a microjet system that delivers medications directly into tissues, matching the effectiveness ...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder
A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential ...